Efficacy of olocizumab in treatment of COVID-19 patients
Background. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim. To study in real clinical practice the efficacy and safety of using the IL-6in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Scientific Сentre for Family Health and Human Reproduction Problems
2022-12-01
|
| Series: | Acta Biomedica Scientifica |
| Subjects: | |
| Online Access: | https://www.actabiomedica.ru/jour/article/view/3828 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251641920847872 |
|---|---|
| author | T. V. Goma A. N. Kalyagin O. V. Ryzhkova N. S. Soloveva |
| author_facet | T. V. Goma A. N. Kalyagin O. V. Ryzhkova N. S. Soloveva |
| author_sort | T. V. Goma |
| collection | DOAJ |
| description | Background. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim. To study in real clinical practice the efficacy and safety of using the IL-6inhibitor (olokizumab) in treatment of patients with confirmed COVID-19 pneumonia.Materials and methods. The first group included 41 hospitalized patients with confirmed COVID-19 pneumonia having complex therapy including olokizumab. The control group consisted of 66 patients with confirmed COVID-19 pneumonia who did not have therapy with IL-6 inhibitor. We analyzed clinical (volume of lung involvement, respiratory failure degree, body mass index) and laboratory data (levels of T-troponin, lactate, procalcitonin, natriuretic peptide, C-reactive protein, fibrinogen, D-dimer, ferritin, erythrocyte sedimentation rate, glomerular filtration rate).Results. The groups did not differ in gender, age, body mass index of patients, volume of lung tissue injury, and duration of hospitalization (p > 0.05). Respiratory failure of 2–3rd degree was more common in patients of the first group (χ2 = 6.3; p = 0.010). The initial levels of C-reactive protein (50.9 [34.2; 76.2] and 32.2 [9.9; 69.1] mg/L respectively; p = 0.009) and fibrinogen (6.0 [5.3; 6.7] and 5.2 [4.3; 6.2] g/l respectively; p = 0.005) in patients having therapy including olokizumab were significantly higher than in the control group. The levels of erythrocyte sedimentation rate, fibrinogen and ferritin, D-dimer, detected upon admission of patients to the hospital, didn’t have statistically significant differences. At discharge, the erythrocyte sedimentation rate in patients receiving olokizumab was statistically significantly lower (9.0 [5.5; 14.5] and 13.0 [7.0; 27.0] mm/h; p = 0.018).Conclusions. Using olokizumab in the treatment patient with COVID-19 pneumonia has demonstrated a positive effect on clinical and laboratory parameters (erythrocyte sedimentation rate, fibrinogen level) in patients with pronounced inflammatory changes and respiratory impairment. |
| format | Article |
| id | doaj-art-198b91e0cdfb4b1e8ebb3db9e7373f9e |
| institution | Kabale University |
| issn | 2541-9420 2587-9596 |
| language | Russian |
| publishDate | 2022-12-01 |
| publisher | Scientific Сentre for Family Health and Human Reproduction Problems |
| record_format | Article |
| series | Acta Biomedica Scientifica |
| spelling | doaj-art-198b91e0cdfb4b1e8ebb3db9e7373f9e2025-08-20T03:56:54ZrusScientific Сentre for Family Health and Human Reproduction ProblemsActa Biomedica Scientifica2541-94202587-95962022-12-0175-2869510.29413/ABS.2022-7.5-2.92439Efficacy of olocizumab in treatment of COVID-19 patientsT. V. Goma0A. N. Kalyagin1O. V. Ryzhkova2N. S. Soloveva3Irkutsk State Medical UniversityIrkutsk State Medical UniversityIrkutsk State Medical UniversityR-Pharm JSCBackground. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim. To study in real clinical practice the efficacy and safety of using the IL-6inhibitor (olokizumab) in treatment of patients with confirmed COVID-19 pneumonia.Materials and methods. The first group included 41 hospitalized patients with confirmed COVID-19 pneumonia having complex therapy including olokizumab. The control group consisted of 66 patients with confirmed COVID-19 pneumonia who did not have therapy with IL-6 inhibitor. We analyzed clinical (volume of lung involvement, respiratory failure degree, body mass index) and laboratory data (levels of T-troponin, lactate, procalcitonin, natriuretic peptide, C-reactive protein, fibrinogen, D-dimer, ferritin, erythrocyte sedimentation rate, glomerular filtration rate).Results. The groups did not differ in gender, age, body mass index of patients, volume of lung tissue injury, and duration of hospitalization (p > 0.05). Respiratory failure of 2–3rd degree was more common in patients of the first group (χ2 = 6.3; p = 0.010). The initial levels of C-reactive protein (50.9 [34.2; 76.2] and 32.2 [9.9; 69.1] mg/L respectively; p = 0.009) and fibrinogen (6.0 [5.3; 6.7] and 5.2 [4.3; 6.2] g/l respectively; p = 0.005) in patients having therapy including olokizumab were significantly higher than in the control group. The levels of erythrocyte sedimentation rate, fibrinogen and ferritin, D-dimer, detected upon admission of patients to the hospital, didn’t have statistically significant differences. At discharge, the erythrocyte sedimentation rate in patients receiving olokizumab was statistically significantly lower (9.0 [5.5; 14.5] and 13.0 [7.0; 27.0] mm/h; p = 0.018).Conclusions. Using olokizumab in the treatment patient with COVID-19 pneumonia has demonstrated a positive effect on clinical and laboratory parameters (erythrocyte sedimentation rate, fibrinogen level) in patients with pronounced inflammatory changes and respiratory impairment.https://www.actabiomedica.ru/jour/article/view/3828olokizumabartelegiacoronavirus infectioncovid-19pneumoniainterleukin 6 |
| spellingShingle | T. V. Goma A. N. Kalyagin O. V. Ryzhkova N. S. Soloveva Efficacy of olocizumab in treatment of COVID-19 patients Acta Biomedica Scientifica olokizumab artelegia coronavirus infection covid-19 pneumonia interleukin 6 |
| title | Efficacy of olocizumab in treatment of COVID-19 patients |
| title_full | Efficacy of olocizumab in treatment of COVID-19 patients |
| title_fullStr | Efficacy of olocizumab in treatment of COVID-19 patients |
| title_full_unstemmed | Efficacy of olocizumab in treatment of COVID-19 patients |
| title_short | Efficacy of olocizumab in treatment of COVID-19 patients |
| title_sort | efficacy of olocizumab in treatment of covid 19 patients |
| topic | olokizumab artelegia coronavirus infection covid-19 pneumonia interleukin 6 |
| url | https://www.actabiomedica.ru/jour/article/view/3828 |
| work_keys_str_mv | AT tvgoma efficacyofolocizumabintreatmentofcovid19patients AT ankalyagin efficacyofolocizumabintreatmentofcovid19patients AT ovryzhkova efficacyofolocizumabintreatmentofcovid19patients AT nssoloveva efficacyofolocizumabintreatmentofcovid19patients |